--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-23-113433" form_type: "8-K" ticker: "QNRX" cik: "0001671502" company_name: "Quoin Pharmaceuticals, Ltd." filed_at: "2023-11-01T23:59:59+00:00" generated_at: "2026-06-09T02:49:01.720385+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.85 calibrated_materiality_score: 0.85 confidence: "high" source: SEC EDGAR --- # Quoin shareholders approve 12x authorized share increase and 1:60,000 reverse split ## Summary - Shareholders approved increasing authorized ordinary shares from 500 billion to 6 trillion. - Reverse stock split at 1-for-60,000 approved; effective date to be set by board. - CEO and COO salaries increased 9.5% retroactive to Jan 1, 2023; CEO $602,250, COO $481,800. - CFO salary raised to $394,200; executive and director option grants approved at $5.75 exercise price. - Non-employee director annual retainer raised to $75,000; annual option grant value reduced to ~$44,000. ## SEC filing metadata - accession: 0001104659-23-113433 - form_type: 8-K - ticker: QNRX - cik: 0001671502 - company_name: Quoin Pharmaceuticals, Ltd. - filed_at: 2023-11-01T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.85 - calibrated_materiality_score: 0.85 - confidence: high - sec_items: 5.02, 5.07, 8.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/0001104659-23-113433-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/tm2329629d1_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-23-113433 - JSON: https://secwatch.observer/filing/0001104659-23-113433.json - Plain text: https://secwatch.observer/filing/0001104659-23-113433.txt ## Key facts - Shareholder Votes Quoin Pharmaceuticals, Ltd. shareholders approved Election of Directors. - Proposal: director election - Outcome: passed source text: (1) The shareholders elected the following directors to serve on the Board of Directors, to serve until Quoin’s 2024 annual meeting of shareholders and until such director’s successor is duly elected and qualified, or until such director’s earlier resignation or retirement, as follows: Directors For Against Abstain Brokers non-vote Dr. Michael Myers 4,714,440,000 1,171,620,000 770,400,000 -- Denise Carter 5,738,640,000 707,160,000 210,660,000 -- Joseph Cooper 5,743,800,000 692,580,000 220,080,000 -- James Culverwell 5,720,880,000 715,140,000 220,440,000 -- Dr. Dennis H. Langer 5,345,160,000 1,115,640,000 195,660,000 -- Natalie Leong 5,754,360,000 694,500,000 207,600,000 -- Michael Sember 5,734,440,000 584,820,000 337,200,000 -- evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/0001104659-23-113433-index.htm - Shareholder Votes Quoin Pharmaceuticals, Ltd. shareholders approved Non-binding advisory vote on the compensation of named executive officers. - Proposal: say on pay - Outcome: passed source text: (10) The shareholders approved, on a non-binding advisory basis, the compensation of Quoin’s named executive officers, as follows: For Against Abstain Brokers non-vote 4,510,560,000 1,855,140,000 290,760,000 -- evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/0001104659-23-113433-index.htm - Shareholder Votes Quoin Pharmaceuticals, Ltd. shareholders approved Approval of an amendment to Articles of Association to increase registered share capital from 500,000,000,000 to 6,000,000,000,000 ordinary shares. - Proposal: charter amendment - Outcome: passed source text: (2) The shareholders approved an amendment to Quoin’s Articles of Association, as amended (the “Articles of Association”), to increase the Company’s registered share capital from 500,000,000,000 ordinary shares, no par value, to 6,000,000,000,000 ordinary shares, no par value, as follows: For Against Abstain Brokers non-vote 4,338,900,000 2,218,020,000 99,540,000 -- evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/0001104659-23-113433-index.htm - Shareholder Votes Quoin Pharmaceuticals, Ltd. shareholders approved Approval of an amendment to the terms of employment of the Chief Operating Officer. - Outcome: passed source text: (5) The shareholders approved an amendment to the terms of employment of Quoin’s Chief Operating Officer, as follows: For Against Abstain Brokers non-vote 4,655,340,000 1,847,220,000 153,900,000 -- evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/0001104659-23-113433-index.htm - Shareholder Votes Quoin Pharmaceuticals, Ltd. shareholders approved Approval of an annual discretionary bonus under the terms of employment of the Chief Executive Officer. - Outcome: passed source text: (6) The shareholders approved an annual discretionary bonus under the terms of employment of Quoin’s Chief Executive Officer, as follows: For Against Abstain Brokers non-vote 1,929,840,000 1,678,440,000 29,100,000 -- evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/0001104659-23-113433-index.htm - Shareholder Votes Quoin Pharmaceuticals, Ltd. shareholders approved Approval of the appointment of Marcum LLP as independent registered public accounting firm. - Proposal: auditor ratification - Outcome: passed source text: (14) The shareholders approved the appointment of Marcum LLP as Quoin’s independent registered public accounting firm until Quoin’s 2024 annual meeting of shareholders, as follows: For Against Abstain Brokers non-vote 6,058,620,000 404,820,000 193,020,000 -- evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/0001104659-23-113433-index.htm - Shareholder Votes Quoin Pharmaceuticals, Ltd. shareholders approved Approval of an amendment to the terms of employment of the Chief Executive Officer. - Outcome: passed source text: (4) The shareholders approved an amendment to the terms of employment of Quoin’s Chief Executive Officer, as follows: For Against Abstain Brokers non-vote 2,535,360,000 1,501,620,000 55,020,000 -- evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/0001104659-23-113433-index.htm - Shareholder Votes Quoin Pharmaceuticals, Ltd. shareholders approved Approval of a grant of options to the Chief Operating Officer. - Outcome: passed source text: (9) The shareholders approved a grant of options to Quoin’s Chief Operating Officer, as follows: For Against Abstain Brokers non-vote 2,222,100,000 1,746,540,000 56,700,000 -- evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/0001104659-23-113433-index.htm - Shareholder Votes Quoin Pharmaceuticals, Ltd. shareholders voted on Non-binding advisory vote on the frequency of future advisory votes on the compensation of executive officers. - Proposal: say on pay frequency source text: (11) The shareholders approved, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of Quoin’s executive officers, as follows: 1Y 2 YR 3 YR Abstain Brokers non-vote 1,677,840,000 65,340,000 4,545,480,000 285,840,000 -- evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/0001104659-23-113433-index.htm - Shareholder Votes Quoin Pharmaceuticals, Ltd. shareholders approved Approval of an annual discretionary bonus under the terms of employment of the Chief Operating Officer. - Outcome: passed source text: (7) The shareholders approved an annual discretionary bonus under the terms of employment of Quoin’s Chief Operating Officer, as follows: For Against Abstain Brokers non-vote 1,943,280,000 1,631,220,000 544,920,000 -- evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/0001104659-23-113433-index.htm - Shareholder Votes Quoin Pharmaceuticals, Ltd. shareholders approved Approval of a grant of options to the Chief Executive Officer. - Outcome: passed source text: (8) The shareholders approved a grant of options to Quoin’s Chief Executive Officer, as follows: For Against Abstain Brokers non-vote 2,128,020,000 1,908,960,000 54,540,000 -- evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/0001104659-23-113433-index.htm - Shareholder Votes Quoin Pharmaceuticals, Ltd. shareholders approved Approval of an amendment to Articles of Association to effect a reverse split at a ratio of 1-for-60,000. - Proposal: reverse split - Outcome: passed source text: (3) The shareholders approved an amendment to Quoin’s Articles of Association to effect a reverse split of the Company’s ordinary shares at a ratio of 1-for-60,000, effective on a date to be determined by the Board of Directors of the Company, as follows: For Against Abstain Brokers non-vote 4,318,680,000 2,230,140,000 107,640,000 -- evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/0001104659-23-113433-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.